Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 17/20 | 0.56 |
| ▸ | DDR1 | Q08345 | 16/20 | 0.56 |
| ▸ | ABL1 | P00519 | 12/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.56 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.56 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.56 |
| ▸ | KIT | P10721 | 2/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | BCR | P11274 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24070472 | 1.00 | DDR2 (0.56) | DDR2DDR1ABL1NTRK1NTRK3 | |
| SCHEMBL24070582 | 0.91 | CSF1R (0.51) | DDR2DDR1ABL1NTRK1NTRK3 | |
| SCHEMBL30211925 | 0.91 | CSF1R (0.51) | DDR2DDR1ABL1NTRK1NTRK3 | |
| SCHEMBL24070474 | 0.85 | DDR2 (0.66) | DDR2DDR1ABL1NTRK1NTRK3 | |
| SCHEMBL24070159 | 0.82 | DDR1 (0.72) | DDR2DDR1ABL1NTRK1NTRK3 | |
| SCHEMBL30446803 | 0.82 | CSF1R (0.51) | DDR2DDR1ABL1NTRK1NTRK3 | |
| SCHEMBL24069891 | 0.82 | CSF1R (0.51) | DDR2DDR1ABL1NTRK1NTRK3 | |
| SCHEMBL24070471 | 0.79 | ABL1 (0.52) | ABL1KITBCRMAPK14 | |
| SCHEMBL24070247 | 0.79 | NR2E1 (0.59) | DDR2DDR1ABL1NTRK3NTRK2 | |
| SCHEMBL30339769 | 0.79 | NR2E1 (0.59) | DDR2DDR1ABL1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| EP-4157447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | DDR2, DDR1, DDRGK1 | DDR2 1/4885DDR1 2/4885ABL1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.